Login to Your Account

Financings Roundup

Friday, January 11, 2013
• Stemline Therapeutics Inc., of New York, again revised the terms for its proposed initial public offering (IPO), increasing the number of shares from 1.8 million to 2.3 million, priced between $10 and $12. At the midpoint range, the offering would bring in $25.3 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription